About Sight Diagnostics
Sight Diagnostics is a company based in Jerusalem (Israel) founded in 2011. Sight Diagnostics has raised $100.26 million across 3 funding rounds from investors including OurCrowd, GO CAPITAL and Koch Disruptive Technologies. Sight Diagnostics offers products and services including Sight 2.0. Sight Diagnostics operates in a competitive market with competitors including Bertis, Audosens, Nourica and SDG3 Health, among others.
- Headquarter Jerusalem, Israel
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$100.26 M (USD)
in 3 rounds
-
Latest Funding Round
$71 M (USD), Series D
Jul 26, 2020
-
Investors
OurCrowd
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sight Diagnostics
Sight Diagnostics offers a comprehensive portfolio of products and services, including Sight 2.0.
Provides advanced technology for blood analysis and diagnostics.
People of Sight Diagnostics
Unlock access to complete
Funding Insights of Sight Diagnostics
Sight Diagnostics has successfully raised a total of $100.26M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $71 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sight Diagnostics
Sight Diagnostics has secured backing from 8 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include OurCrowd, GO CAPITAL and Koch Disruptive Technologies.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Sciences focused VC firm investing in Israel and the US
|
Locked | Locked | Locked | |
|
Longliv Ventures is engaged in funding digital health innovations.
|
Locked | Locked | Locked | |
|
Multiple sectors are invested in by the venture capital firm.
|
Locked | Locked | Locked |
Investor details for Sight Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sight Diagnostics
Investment portfolio details for Sight Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sight Diagnostics
Detailed financials for Sight Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sight Diagnostics Comparisons
Peer comparison for Sight Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sight Diagnostics
Sight Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bertis, Audosens, Nourica and SDG3 Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-based diagnostic platforms for cancer and cardiac diseases are developed.
|
|
| Locked | Locked | Locked |
Diagnostic devices for optical detection of multiple analytes are provided.
|
|
| Locked | Locked | Locked |
Creates innovative non-invasive devices for sweat-based health diagnostics and monitoring.
|
|
| Locked | Locked | Locked |
Develops AI technology for non-invasive anemia screening through mobile applications.
|
Detailed competitors of Sight Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sight Diagnostics
Complete news archive for Sight Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sight Diagnostics
Sight Diagnostics was founded in 2011 and raised its 1st funding round 3 years after it was founded.
Sight Diagnostics is headquartered in Jerusalem, Israel. It is registered at Jerusalem, Jerusalem District, Israel.
Sight Diagnostics is a funded company, having raised a total of $100.26M across 3 funding rounds to date.
Sight Diagnostics developed a platform for blood analysis and infectious disease diagnostics based on its computer vision technology. Its platform is built on sample preparation, biological staining, machine-vision algorithms, and clinical instrumentation, to provide diagnostic solutions that are suitable for point-of-care use. Its first product, the Parasight Malaria Detection platform, identifies, enumerates, and speciates malarial parasites.Currently, it is applying its technology to the 20 billion complete blood count (CBC) market, developing a point-of-care CBC platform which will provide a 5 point differential blood count is expected in the summer 2016.
Sight Diagnostics offers Sight 2.0.
Sight Diagnostics has 8 investors. Key investors include OurCrowd, GO CAPITAL, Koch Disruptive Technologies, Clal Biotechnology Industries, and Longliv Ventures.